Business Description
Xenon Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA98420N1050
Description
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 58.52 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -57.2 | |||||
| 3-Year EPS without NRI Growth Rate | -50.2 | |||||
| 3-Year FCF Growth Rate | -15.4 | |||||
| 3-Year Book Growth Rate | 38.1 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.55 | |||||
| 9-Day RSI | 43.49 | |||||
| 14-Day RSI | 41.58 | |||||
| 6-1 Month Momentum % | 36.99 | |||||
| 12-1 Month Momentum % | 7.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 23.65 | |||||
| Quick Ratio | 23.65 | |||||
| Cash Ratio | 23.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.1 | |||||
| Shareholder Yield % | -0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -25.2 | |||||
| ROA % | -24.03 | |||||
| ROIC % | -109.85 | |||||
| ROC (Joel Greenblatt) % | -1151.83 | |||||
| ROCE % | -29.17 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.29 | |||||
| Price-to-Tangible-Book | 3.29 | |||||
| EV-to-EBIT | -11.2 | |||||
| EV-to-EBITDA | -11.39 | |||||
| EV-to-Forward-Revenue | 603.85 | |||||
| EV-to-FCF | -15.88 | |||||
| Price-to-Projected-FCF | 28.72 | |||||
| Price-to-Net-Current-Asset-Value | 5.02 | |||||
| Price-to-Net-Cash | 5.08 | |||||
| Earnings Yield (Greenblatt) % | -8.93 | |||||
| FCF Yield % | -4.94 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers